Compounded vs Brand GLP-1 Cost (2026)

See if you qualify — start your assessment →
5-minute questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on the 3-month and 6-month plans on 3- and 6-month plans · available in all 50 states

Compounded vs brand GLP-1 cost at a glance (2026)

Prices reflect publicly available information as of June 2026 and change frequently — verify current figures with each manufacturer or provider before making any decision. Compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to the brand-name drugs. See the GLP-1 Telehealth Pricing 2026 dataset for a broader provider comparison.

How the real cost gap works in 2026

For several years, GLP-1 headlines focused on the gap between brand list prices (often $1,000–$1,300/month without insurance) and compounded alternatives at $99–$250. That gap has narrowed significantly. Both Novo Nordisk and Eli Lilly now run direct self-pay programs that bring brand costs down to the $299–$449 range, depending on the drug and dose tier.

That means the honest comparison in 2026 is compounded vs. brand self-pay, not compounded vs. list price. Compounded semaglutide (~$99–$199 all-in) still typically undercuts Wegovy's self-pay program (~$349), and compounded tirzepatide (~$125–$399) overlaps with or undercuts Zepbound's LillyDirect vial tiers ($299–$449), depending on dose. At higher compounded tirzepatide doses, the price gap can be narrow or absent.

The cost comparison also shifts depending on what's included. Some brand programs include wraparound support, pharmacy fulfillment, or nurse-line access; some compounded telehealth providers charge a bare medication price with support billed separately. Always price the full program, not just the vial.

How brand self-pay programs changed the math

Wegovy (semaglutide for weight management). Novo Nordisk's NovoCare program has offered self-pay pricing around $349/month, significantly below the ~$1,349 list price. A limited introductory rate of $199/month was available earlier in 2026 for eligible patients — that offer is time-sensitive, so verify current availability directly at the Wegovy NovoCare page before citing it.

Zepbound (tirzepatide for weight management). Eli Lilly's LillyDirect program offers self-injection vials in three dose tiers — roughly $299, $399, and $449/month depending on the dose — accessed through the LillyDirect platform. The program has specific eligibility and access conditions; confirm those on Lilly's site at the time you're evaluating your options.

Mounjaro and Ozempic are primarily indicated for type 2 diabetes; self-pay programs and savings cards vary and may not be available for weight-loss use specifically. Confirm with the manufacturer if this applies to you.

These self-pay programs matter because they are the relevant comparison for most people without insurance coverage — not the sticker price.

The teaser-pricing trap

The biggest pitfall on the compounded side isn't the medication cost — it's undisclosed membership fees. A "$99/month" headline typically refers only to the medication vial. Providers commonly charge a separate platform or membership fee of $49–$79/month, bringing the real all-in cost to $148–$178 or more.

Before enrolling with any compounded GLP-1 provider, ask these questions explicitly:

• What is the total monthly charge, including any membership, subscription, platform, or clinical-consult fee?
• Is the per-dose price the same at all doses (i.e., does going from 0.5 mg to 1 mg semaglutide cost more)?
• Is ongoing prescriber access included, or billed separately?
• Are nutrition or lifestyle support included, or add-ons?

Some providers advertise "$99/month" for semaglutide and $79/month for a platform subscription, resulting in an effective $178/month — comparable to, or higher than, more transparent all-in pricing from other providers.

What "not FDA-approved" actually means

This is the most important factual difference between compounded and brand GLP-1 medications. "Not FDA-approved" is not a technicality — it means the FDA has not reviewed the compounded product for safety, effectiveness, or manufacturing quality.

For brand-name drugs like Wegovy, Ozempic, Zepbound, and Mounjaro, FDA approval required multi-year Phase 3 clinical trials involving thousands of participants, demonstrating specific safety and efficacy outcomes before the drug could be marketed. The STEP trials established the evidence base for semaglutide as a weight-management drug; the SURMOUNT trials did the same for tirzepatide — research on those branded molecules, under those specific formulations, following those manufacturing processes.

Compounded medications do not go through that review process. Per the FDA's compounding guidance, compounding is legal under specific conditions — a valid prescription, a licensed compounding pharmacy, and preparation for an individual patient's needs — but the resulting product is not FDA-approved. The FDA has noted that it has received adverse event reports involving compounded semaglutide and tirzepatide, and it advises patients to be aware of the risks of compounded products from facilities it has not reviewed. See the FDA's postmarket drug safety information for current guidance.

This does not make compounded GLP-1s inherently dangerous — millions of prescriptions have been dispensed by licensed 503A pharmacies under clinician supervision. But it is a real, material difference that every patient should understand before choosing between the two options.

How access and prescribing works for each path

Both require a prescription. GLP-1 medications — compounded or brand — are prescription drugs in the United States. They are not available over the counter. Eligibility is determined by a licensed clinician based on your individual health profile.

Per the National Institute of Diabetes and Digestive and Kidney Diseases, prescription weight-management medications are generally indicated for adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition.

Brand path. Getting a brand-name GLP-1 typically means a clinician sends a prescription to a retail or specialty pharmacy, then navigating insurance prior authorization (often denied for weight management) or enrolling in a manufacturer savings program. Wait times for initial visits and fulfillment vary widely. Insurance coverage for brand GLP-1s used for weight management remains limited; many commercial plans and Medicare historically exclude this indication, though the landscape is evolving.

Compounded telehealth path. A telehealth provider sends a prescription to a licensed compounding pharmacy; the pharmacy prepares and ships the medication directly. Turnaround tends to be faster than the insurance-approval route for brand drugs. The trade-off is that you are taking a product that has not gone through the FDA's review process for the compounded formulation.

Either way, the prescriber should be reviewing your full health intake — not rubber-stamping requests. If a provider skips a meaningful clinical review, that is a red flag regardless of which medication type they offer.

503A vs 503B compounding pharmacies: what you need to know

When you see a compounded GLP-1 advertised, the pharmacy behind it is almost certainly operating under one of two frameworks:

503A (patient-specific compounding). A 503A pharmacy compounds medications for individual patients based on valid prescriptions. It is licensed by the state, not the FDA, and does not produce large batches for general distribution. The overwhelming majority of compounded GLP-1 prescriptions come from 503A pharmacies. Nouri uses 503A pharmacies: Jungle Jim's Pharmacy (Fairfield, OH) and VialsRX.

503B (outsourcing facilities). A 503B outsourcing facility produces larger-volume batches and operates under FDA facility oversight — not FDA product approval. 503B is a higher bar for the facility, but it still does not result in an FDA-approved product. Some 503B facilities operate at scale; others may be newer entrants with less track record.

Neither type produces an FDA-approved product. The key verification steps for either:

• The provider names the pharmacy — any legitimate operation will tell you where your medication is compounded.
• You can independently verify the pharmacy's license through your state's board of pharmacy database.
• The pharmacy is not selling directly to consumers without a prescription — that is not legal compounding.

Be skeptical of providers that decline to name their pharmacy or who claim their source is a "certified" or "FDA-approved" compounding facility — no compounded GLP-1 product is FDA-approved.

What to compare: a total-cost checklist

Before enrolling with any compounded GLP-1 provider, nail down the following costs in writing:

Once you have the full picture, compare that all-in monthly number — not the headline.

Where Nouri fits on cost

Nouri's compounded GLP-1 program is priced transparently — one number covers everything: the compounded medication (when prescribed), a personalized nutrition plan, a movement plan, and ongoing clinician support. There is no membership add-on, no per-dose surcharge, and no per-consult billing.

Nouri is not positioned as the cheapest option — some compounded providers list lower headline prices, though those often carry the membership fees described above. Nouri's angle is transparency: one all-in price that includes the full clinical program, at any dose, in all 50 states. Nouri is LegitScript-certified and names its compounding pharmacies (Jungle Jim's Pharmacy, a licensed 503A in Fairfield, OH, and VialsRX).

The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on the 3-month and 6-month plans. Compounded medications are not FDA-approved and are not the same as the brand-name drugs; medication is prescribed only if clinically appropriate after review by a licensed provider. Not all applicants qualify.

See full pricing and eligibility at joinnouri.com/becoming.

Can you use an HSA or FSA for a compounded GLP-1?

Potentially — but with important qualifications. Compounded GLP-1 medications prepared under a lawful prescription from a licensed pharmacy may be eligible for reimbursement through a Health Savings Account (HSA) or Flexible Spending Account (FSA) as a qualified medical expense under IRC §213(d). Reimbursement typically requires a receipt and, in some cases, a letter of medical necessity from your prescribing provider.

However, HSA/FSA rules are plan-specific and interpretation varies. Do not assume your plan covers this cost. Confirm eligibility with your plan administrator and, for tax questions, consult a tax professional. Nouri does not accept HSA/FSA cards directly; this applies to reimbursement claims only. For a full breakdown, see our guide to using HSA/FSA for GLP-1 medications.

Related cost guides

• GLP-1 Cost 2026: Complete Guide (All Drugs, All Paths)
• Semaglutide Cost With and Without Insurance
• Tirzepatide Cost Without Insurance
• Wegovy Cost Without Insurance (2026)
• Zepbound Cost Without Insurance (2026)
• Compounded Semaglutide vs. Wegovy: What's the Difference?
• Compounded Tirzepatide vs. Zepbound: What's the Difference?
• Cheapest Way to Get a GLP-1 (Full Cost Comparison)

Frequently asked questions

How much does compounded semaglutide cost per month?

Typically $99–$199/month all-in via telehealth, though many low headline prices carry a separate $49–$79 monthly membership fee that raises the real total. Always ask for the all-in monthly number. Compounded semaglutide is not FDA-approved and is not the same as Wegovy or Ozempic.

Is compounded semaglutide cheaper than Ozempic?

Usually cheaper on sticker — compounded semaglutide runs ~$99–$199/month all-in vs. Ozempic self-pay around $349/month (as of June 2026, per NovoCare). But compounded semaglutide is not FDA-approved, and you should compare the all-in price including any membership or platform fee before concluding you're saving money.

Is compounded GLP-1 FDA-approved?

No. Compounded GLP-1 medications — including compounded semaglutide and compounded tirzepatide — are not FDA-approved. The FDA has not reviewed the compounded product for safety, efficacy, or quality. Compounding from a state-licensed 503A pharmacy under a valid prescription is legal, but it is not the same as an FDA-approved drug. Use a provider that names and verifies its pharmacy.

What is the real all-in monthly cost of compounded semaglutide?

Often higher than the headline. A "$99/month" medication price frequently comes with a separate $49–$79 monthly membership or platform fee, making the real cost $148–$178/month or more. Ask any provider: "What is my total monthly charge, all fees included, at each dose?" before enrolling.

What is the difference between 503A and 503B compounding pharmacies?

A 503A pharmacy compounds patient-specific medications under a valid prescription and is licensed by the state. A 503B outsourcing facility produces larger batches under FDA facility oversight — a higher operational bar, but still not FDA drug approval. Neither produces an FDA-approved product. The key verification step for either: the provider names the pharmacy, and you can look it up in the state board of pharmacy database.

Why is compounded tirzepatide cheaper than Zepbound?

Because it doesn't carry the manufacturing, clinical-trial, and regulatory costs of an FDA-approved brand-name drug. It's prepared by a compounding pharmacy under a patient-specific prescription. Compounded tirzepatide typically runs ~$125–$399/month versus Zepbound's LillyDirect self-pay tiers at $299–$449/month by dose. Prices change — verify current figures directly. Compounded tirzepatide is not FDA-approved and is not the same as Zepbound.

Sources and references

1. FDA: Human Drug Compounding — Questions and Answers (U.S. Food & Drug Administration)
2. FDA: Postmarket Drug Safety Information for Patients and Providers (U.S. Food & Drug Administration)
3. Prescription Medications to Treat Overweight & Obesity (National Institute of Diabetes and Digestive and Kidney Diseases, NIH)
4. CMS: $50/month Access to GLP-1 Medications for Medicare Beneficiaries (Centers for Medicare & Medicaid Services)
5. Wegovy Self-Pay & Savings — NovoCare (Novo Nordisk; verify current pricing before citing)
6. Zepbound Self-Pay Vials — LillyDirect (Eli Lilly; verify current pricing and program terms before citing)
7. GLP-1 Drugs: Cost and Savings Guide (GoodRx, for market pricing context; verify figures at time of use)
8. GLP-1 Telehealth Pricing 2026 Dataset (Nouri; provider pricing data, June 2026)

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as pricing and regulations change.

Medical disclaimer: This article is general educational information about medication cost and access, not medical advice. GLP-1 medications are prescription drugs; eligibility is determined by a licensed clinician based on your individual health. Not all applicants qualify for Nouri's program. Compounded semaglutide and compounded tirzepatide are not FDA-approved drugs and are not the same as, or therapeutically equivalent to, Wegovy®, Ozempic®, Zepbound®, or Mounjaro®. The FDA has not verified the safety, efficacy, or quality of compounded GLP-1 preparations. Compounding from a state-licensed 503A pharmacy with a valid prescription is legal, but the product is not FDA-approved.

Safety information: GLP-1 medications carry a boxed warning for thyroid C-cell tumors. Do not use if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Stop use and contact your provider if you experience symptoms of a serious allergic reaction, pancreatitis, or gallbladder problems; these medications are not for use during pregnancy. Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. Talk to your provider about all risks before starting treatment.

Pricing disclaimer: All prices are accurate as of June 2026 and change frequently. Verify current figures with each manufacturer, your pharmacy, and your insurer on the day you make a decision. Brand pricing from manufacturer self-pay or savings programs is subject to eligibility and program terms. Nouri pricing reflects the 6-month plan; see joinnouri.com/becoming for all plan options. Any Nouri price stated in this article must be confirmed against the current listing at joinnouri.com/becoming before publishing.

FSA/HSA disclaimer: HSA/FSA reimbursement eligibility for compounded GLP-1 medications varies by plan. This is not tax or financial advice. Confirm eligibility with your plan administrator and consult a qualified tax professional.

Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Nouri is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.